AMA Manual of Style - Stacy L. Christiansen, Cheryl Iverson 2020
Acknowledgments (Article Information)
Manuscript Preparation for Submission and Publication
Acknowledgments is the blanket term used to cover the information that follows the body of the article and precedes the references and is also known as Article Information. For authors preparing manuscripts for submission, the Acknowledgment section may include information about the authors that is not included on the title page(s) (eg, author contributions and conflict of interest disclosures), information about the manuscript (eg, funding and role of sponsor), acknowledgment of nonauthor collaborators or other contributors, and any previous presentation of the material. The Acknowledgment section is considered a continuation of the text, so that abbreviations introduced in the text may stand without expansion here.
For purposes of publication, if a footnote that would normally appear on the first page of the print or PDF version of an article (eg, the affiliation footnote) is too long to be placed on the first page, it may be placed here immediately after the acceptance date and, if applicable, the online publication information; if the journal does not publish acceptance dates, the affiliation footnote that did not fit on the first page would be placed first in the Acknowledgment section. Online, Acknowledgment sections are typically placed at the end of the article. The JAMA Network journals publish Acknowledgments as Article Information (see 2.3.1, Order of Footnotes for Print or PDF Page, where some additional types of acknowledgment footnotes are discussed [placement of such footnotes may vary among journals]). Examples of various parts of the Acknowledgment section (also called Article Information) follow, as used by the JAMA Network journals (see 5.2.3, Author Contributions, Box 5.2-1. Hypothetical Example of an Acknowledgment or Article Information Section, Including Order of All Possible Elements, for a list of the order of all possible elements that may appear in the Acknowledgments section).
2.10.1 Manuscript History: Submission and Acceptance Dates.
Some journals include the date of the manuscript’s acceptance; others include the date of manuscript submission, the date the revision was received, and the date the manuscript was accepted. This is done in the interest of transparency and may be more important in the basic sciences. Examples are shown below:
Submitted for Publication: December 2, 2018; accepted February 11, 2019.
Accepted for Publication: September 15, 2018.
2.10.2 Publication Online First or Online Only.
If an article was published online first or online only, the date it was published online, along with the DOI, a unique character string that identifies an object on a digital network, should follow the acceptance date footnote (or, if the journal does not publish the acceptance date, it should be placed first).
Published Online: March 4, 2019. doi:10.1001/jamapediatrics.2019.0025
Published Online: March 7, 2019. doi:10.1001/jama.2019.1608
2.10.3 Information on Open Access.
If an article is published under an open access license, that information can be displayed as follows:
Open Access: This is an open access article distributed under the terms of the CC-BY License. ©2018 Sestak I et al. JAMA Oncology.
2.10.4 Corrections.
If an article has been corrected since publication, this is noted formally in the Acknowledgment section and includes the date the error was fixed and a description of the error. Note: These notes do not replace the need for a published erratum (see 5.11.10, Corrections [Errata]).
Correction: This article was corrected on May 20, 2014, to fix a typographical error in the abstract and on July 3, 2014, to fix a numerical error in the Secondary Outcomes subsection in the Results section.
Correction: This article was corrected on February 28, 2019, to correct an omission of 2 reference citations and to add discussion of these related studies to the article introduction.
Correction This article was corrected on January 13, 2019, to fix a numerical error in the first column of Table 2.
2.10.5 Author Affiliation Notes.
On the journal’s website, author affiliation notes or a link to the notes may appear just below the author names. Limited space on the first page of a print or PDF version of an article may sometimes preclude setting the author affiliation footnote on the first page. If the author affiliation footnote does not fit there, it should appear at the end of the article, after the acceptance date and the online-first or online-only information, if applicable.
2.10.6 Group Information.
The place in the manuscript where the members of the group are listed should be provided.
Group Information: The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network members are listed at the end of the article.
2.10.7 Corresponding Author Contact Information.
Contact information for the corresponding author (street address, if possible, with zip or postal code, and email address) is provided in a footnote. Even if there is only a single author, the full name of the person should be included. Follow the custom of individual countries regarding the placement of the zip or postal code. Note: For the JAMA Network journals, this information is provided on the first page of the print or PDF version of the article and at the beginning of Article Information of the online version.
Corresponding Author: John H. Alexander, MD, MS, Box 3300, Duke University Medical Center, Durham, NC 27715 (john.h.alexander@duke.edu).
Corresponding Author: Patrick J. Gullane, MB, University Health Network, University of Toronto, 200 Elizabeth St, Ste 8N-800, Toronto, ON M5G 2C4, Canada (patrick.gullane@uhn.on.ca).
Corresponding Author: Christoph Kniestedt, MD, Department of Ophthalmology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8400 Winterthur, Switzerland (research@kniestedt.ch).
Corresponding Author: Tomoyuki Kawada, MD, PhD, Department of Hygiene and Public Health, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo 113-8602, Japan (kawada@nms.ac.jp).
Corresponding Author: N. J. Hall, MD, Department of Pediatric Surgery, Institute of Child Health, 30 Guilford St, London WC1N 1EH, England (n.hall@ich.ucl.ac.uk).
Corresponding Author: Jacqueline C. M. Witteman, PhD, Department of Epidemiology and Biostatistics, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, the Netherlands (j.witteman@erasmusmc.nl).
Although traditionally only a single author has been allowed to be designated as corresponding author, the JAMA Network journals now allow a maximum of 2 corresponding authors on a published article—with justification—provided that only 1 person be responsible for all communications during and after publication. This person will be listed first.12
For authors from the same institution:
Corresponding Authors: Jie Qiao, MD, PhD (jie.qiao@263.net), and Tianpei Hong, MD, PhD (tpho66@bjmu.edu.cn), Peking University Third Hospital, 49 N Garden Rd, Haidian District, Beijing 100191, China.
For authors from the same institution but different departments:
Corresponding Authors: Jie Qiao, MD, PhD, Center of Reproductive Medicine (jie.qiao@263.net), and Tianpei Hong, MD, PhD, Department of Endocrinology and Metabolism (tpho66@bjmu.edu.cn), Peking University Third Hospital, 49 N Garden Rd, Haidian District, Beijing 100191, China.
For authors from different institutions:
Corresponding Authors: Linhong Wang, PhD, National Center for Chronic Noncommunicable Diseases Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China (linhong@chinawch.org.cn); Yonghua Hu, MD, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China (yhhu@bjmu.edu.cn).
In the print or PDF version, for smaller items with signature blocks rather than bylines (eg, letters to the editor, book reviews), the signature block shows the authors’ complete names and degrees only. In notes that follow the signature block, the Author Affiliation note indicates the authors’ affiliations and the Corresponding Author note provides the complete name and address (including email address) of the corresponding author.
Signature block:
John C. Newman, MD, PhD
Michael A. Steinman, MD
Author Affiliations: Division of Geriatrics, University of California, San Francisco.
Corresponding Author: John C. Newman, MD, PhD, Division of Geriatrics, University of California, San Francisco, 4150 Clement St, Ste 181G, San Francisco, CA 94121 (newman@ucsf.edu).
Print or PDF Version
Signature block:
Sarah E. Sasor, MD
Naveed N. Nostrati, MD
Terrence Katona, DO
William A. Wooden, MD
Adam Cohen, MD
Imtiaz A. Munshi, MD
Sunil S. Tholpady, MD, PhD
Author Affiliations: Division of Plastic Surgery, Department of Surgery, Indiana University, Indianapolis (Sasor, Nostrati, Wooden, Tholpady); Richard L. Roudebush VA Medicine Center, Indianapolis, Indiana (Katona, Wooden, Cohen, Munshi, Tholpady).
Corresponding Author: Sunil S. Tholpady, MD, PhD, Division of Plastic Surgery, Department of Surgery, Indiana University, 705 Riley Hospital Dr, RI2514, Indianapolis, IN 46202 (stholpad@iupui.edu).
Online Version
Signature Block (Byline): Sarah E. Sasor, MD1; Naveed N. Nostrati, MD1; Terrence Katona, DO2; William A. Wooden, MD1,2; Adam Cohen, MD2; Imtiaz A. Munshi, MD2; Sunil S. Tholpady, MD, PhD1,2
Links to Affiliations
1Division of Plastic Surgery, Department of Surgery, Indiana University, Indianapolis
2Richard L. Roudebush VA Medical Center, Indianapolis, Indiana
There is no need to set the email address in italics or to precede it by the word email. Do not add a hyphen to the address to indicate a line break.
2.10.8 Author Contributions.
Editors may ask authors to describe what each author contributed to the work, and the list of contributions may be published at the editor’s discretion. This is done in all JAMA Network journals (see 5.1.1, Authorship: Definition, Criteria, Contributions, and Requirements). The JAMA Network journals require authors of manuscripts reporting original research and reviews to provide an “access to data” statement (see 5.1.1, Authorship: Definition, Criteria, Contributions, and Requirements). If such a statement is provided, it is given under the head Author Contributions, before the other contributions.
Author Contributions: Drs Hartnick and Raol had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: De Guzman, Ballif, Hartnick.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: De Guzman, Hartnick, Raol.
Critical revision of the manuscript for important intellectual content: De Guzman, Ballif, Hartnick, Raol.
Statistical analysis: Maurer, Hartnick, Raol.
Administrative, technical, or material support: De Guzman, Ballif, Hartnick, Raol.
Supervision: Hartnick.
2.10.9 Conflict of Interest Disclosures.
Authors are expected to provide detailed information about “financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript), employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.”8 Following the guidelines of the ICMJE,1 the definitions and terms of such disclosures include the following:
■any potential conflicts of interest “involving the work under consideration for publication” (during the time involving the work, from initial conception and planning to present)
■any “relevant financial activities outside the submitted work” (during the 3 years before submission)
■any “other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing” what is written in the submitted work (based on all relationships that were present during the 3 years before submission)
See also 5.5, Conflicts of Interest.
Authors are expected to provide detailed information about any potential competing interests or conflicts, particularly those present at the time the research was conducted and up to the time of publication, as well as other financial interests, such as relevant filed or pending patents or patent applications in preparation, that represent potential future financial gain. Although many universities and other institutions and organizations have established policies and thresholds for reporting financial interests and other conflicts of interest, the JAMA Network journals require complete disclosure of all relevant financial relationships and potential financial conflicts of interest, regardless of amount or value. If authors are uncertain about what might constitute a potential conflict of interest, they should err on the side of full disclosure and contact the editorial office if they have questions or concerns. In addition, authors who have no relevant conflicts of interest are asked to provide a statement indicating that they have no conflicts of interest related to the material in the manuscript.
For some journals, conflict of interest disclosure information is for use in the editorial office and is not shared with peer reviewers. Other journals, such as the JAMA Network journals, require authors to include all such disclosures in the Acknowledgment section of the manuscript, which is shown to peer reviewers. For all accepted manuscripts, each author’s disclosures of relevant conflicts of interest or declarations of no conflicts of interest should be published. Decisions about whether conflict of interest disclosure information provided by authors should be published, and thereby disclosed to readers, are usually straightforward. Although editors are willing to discuss publication of specific conflict of interest disclosures with authors, the policy of the JAMA Network journals is one of full disclosure of all relevant conflicts of interest.
Policies requiring disclosure of conflicts of interest should apply to all manuscript submissions, including letters to the editor, opinion pieces, informal essays, reviews of books and other media, and online comments.
Below are examples of conflict of interest disclosure statements.
Conflict of Interest Disclosures: Dr Ware reported owning shares in and receiving regular income from an Australian company, Cyclotek Pty Ltd, which sells positron emission tomography radiopharmaceuticals, including fludeoxyglucose. No other disclosures were reported.
Conflict of Interest Disclosures: Dr Morrow reported receiving research grant support administered via Brigham and Women’s Hospital from Bayer Healthcare Diagnostics, Beckman Coulter, Biosite, Dade Behring, Merck, and Roche Diagnostics and having received honoraria for educational presentations from Bayer Healthcare Diagnostics, Beckman Coulter, and Dade Behring. Dr de Lemos reported receiving research grants and honoraria and consulting fees for speaking from Biosite and Roche. Dr Blazing reported receiving honoraria from Merck and Pfizer.
Conflict of Interest Disclosures: Dr Chang reported having been a clinical investigator for studies sponsored by Lilly Infinity, Genentech, and Novartis. No other disclosures were reported.
Conflict of Interest Disclosures: Dr Callen reported receiving an honorarium for consulting for GlaxoSmithKline and serving on a safety monitoring committee for Celgene. No other disclosures were reported.
Conflict of Interest Disclosure: Dr Neuzil reported receiving research funding from MedImmune for participation in a multicenter trial of a live attenuated influenza vaccine in 2004-2005.
Conflict of Interest Disclosure: Dr Smith reported serving as an expert witness for plaintiffs in US tobacco litigation.
Note: The conflict of interest disclosure may be a disclosure of no conflicts of interest.
Conflict of Interest Disclosures: None reported.
2.10.10 Funding/Support.
Each author should provide detailed information regarding all financial and material support for the research and work, including but not limited to grant support, funding sources, and provision of equipment and supplies. This is outlined in the journals’ instructions for authors (see 2.10.10, Manuscript Preparation for Submission and Publication, Acknowledgments, Funding/Support, and 5.5.3, Reporting Funding, Sponsorship, and Other Support).
All financial and material support for the research and work should be clearly and completely identified in the Acknowledgment section. Grant or contract numbers should be included whenever possible. The complete name of the funding institution or agency should be given.
If individual authors were the recipients of funds, their names should be listed parenthetically.
Funding/Support: This study was supported in part by grant CA34988 from the National Cancer Institute, National Institutes of Health, and a teaching and research scholarship from the American College of Physicians (Dr Fischl).
Funding/Support: This study was supported by the Gladstone Institute of Virology and Immunology Center for AIDS Research Evaluation and Allocation Committee, University of California, San Francisco; grant K23EY019071 from the National Institutes of Health, National Eye Institute; and That Man May See, the Littlefield Trust, the Peierls Foundation, and the Doris Duke Charitable Foundation through a grant supporting the Doris Duke International Clinical Research Fellows Program at the University of California, San Francisco. Mr Yen is a Doris Duke International Clinical Research Fellow.
Funding/Support: This study was supported by grants 81170881 and U1201221 from the National Science Foundation of China, grant 2010CB529904 from the national 973 Program, Project 984 of Sun Yat-Sen University, and fundamental research funds of the State Key Laboratory of Ophthalmology (Dr Zhang).
Funding/Support: This study was supported by a 2000 Special Projects Award of the Ambulatory Pediatric Association (Dr Hickson).
Funding/Support: This work was supported by research grant R01 MH45757 from the National Institute of Mental Health (Dr Klein).
Funding/Support: Funding for this study was provided by grant 5 U18 HS011885 from the Agency for Healthcare Research and Quality and through subcontracts with the Utah Department of Health (contract 026429) and the Missouri Department of Health and Senior Services (contract AOC02380132).
Funding/Support: This study was supported by Merck and Co and Bayer Healthcare Diagnostics Division.
Funding/Support: Alefacept was provided to the patients at no cost through a Biogen Idec patient assistance program.
2.10.11 Role of the Funders/Sponsors.
The specific role of the funding organization or sponsor in each of the following should be specified: design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. For articles that do not include original research, “design and conduct of the study and collection, management, analysis, and interpretation of the data” is omitted (see 5.5.4, Reporting the Role of the Sponsor).
Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Role of the Funders/Sponsors: Staff from Merck assisted in monitoring the progress and conduct of the A to Z trial. Bayer Healthcare provided reagents for B-type natriuretic peptide testing. The sponsors were not involved in the biomarker testing, analysis, or interpretation of the data or in preparation of the manuscript for this substudy. Medical specialists employed by the sponsors reviewed the manuscript before submission.
2.10.12 Group Information (Including List of Participants in a Group).
If the study was performed by a group of persons, the names of the participants may be listed in the Acknowledgment section (see 2.3.3, Author Affiliations). It is important to separately identify and tag members of the group who are authors, members of the group who are nonauthor collaborators, and other members of the group (see 5.2.2, Group and Collaborative Author Lists).
2.10.13 Disclaimer.
A note of disclaimer is used to separate the views of the authors from those of employers, funding agencies, organizations, or others. Editors should generally retain the author’s phrasing, especially if such phrasing is required by the policy of the entity mentioned.
Disclaimer: The views expressed here are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or the US government.
Disclaimer: The opinions expressed herein are only those of the authors. They do not represent the official views of the government of India, St Michael’s Hospital, the University of Toronto, or the study sponsors.
Disclaimer: Use of trade names or names of commercial sources is for information only and does not imply endorsement by the US Public Health Service or the US Department of Health and Human Services.
Disclaimer: Opinions in this article should not be interpreted as the official position of the International Committee of the Red Cross.
Disclaimer: The opinions expressed herein are those of the authors and do not necessarily reflect the views of the Indian Health Service.
If the byline of a research manuscript includes an editor of the journal, the following type of disclaimer is useful.
Disclaimer: Dr Bressler is the editor of JAMA Ophthalmology. He was not involved in the editorial evaluation of or decision to accept this article for publication.
2.10.14 Meeting Presentation.
The following formats are used for material that has been read or exhibited at a professional meeting. The original spelling and capitalization of the meeting name should be retained. Provide the exact date and location of the meeting (see 5.3, Duplicate Publication and Submission).
Meeting Presentation: This study was presented at the Society of Critical Care Medicine’s 48th Critical Care Congress; February 18, 2019; San Diego, California.
Meeting Presentation: This work was presented at the annual meeting of the Association for Research in Vision and Ophthalmology; May 5, 2013; Seattle, Washington; at the annual meeting of the American Society of Retina Specialists; August 25, 2013; Toronto, Canada; and at the 47th Annual Meeting of the Microbiology and Immunology Group; November 15, 2013; New Orleans, Louisiana.
Meeting Presentation: This study was presented at the Annual Heart Rhythm Society Scientific Sessions; May 10, 2018; Boston, Massachusetts.
2.10.15 Previous Posting.
For manuscripts and articles that have been previously posted to a preprint server, the following formats may be used. The original spelling and capitalization of the preprint server name should be retained. A URL or DOI link to the posting date may also be included (see 5.6.2, Public Access and Open Access in Scientific Publication).
Previous Posting: This article was posted as a preprint on bioRxiv.org.
Previous Posting: This manuscript was posted as a preprint on bioRxiv.org on November 9, 2018. doi:https://doi.org/10.1101/465013
Previous Posting: This manuscript was posted as a preprint on PeerJPreprints. 2018;6:e26857v4. doi:https://doi.org/10.7287/peerj/preprints.26857v4
2.10.16 Data Sharing Statement.
For reports of randomized clinical trials, ICMJE recommends that authors of clinical trials provide a data sharing statement with submitted manuscripts and indicate if data, including individual patient data, a data dictionary that defines each field in the data set, and supporting documentation, will be made available to others; when, where, and how the data will be available; types of analyses that are permitted; and if there will be any restrictions on the use of the data.13 This follows a previous ICMJE requirement for authors of clinical trials to also include trial protocols with submitted manuscripts and published articles. Data sharing statements may also be submitted for reports of other types of studies, but the ICMJE member journals only require this for reports of clinical trials.
The data sharing statements should address the following items:
Data
Will the data collected for your study, including individual patient data and a data dictionary defining each field in the data set, be made available to others?
Yes or no. (If no, authors may explain why data are not available.)
List all data that will be made available:
■Deidentified participant data
■Participant data with identifiers
■Data dictionary
■Other (please specify)
List where to access these data. Provide complete URL if data will be available in a repository or website, or provide complete email address if request for data must be sent to an individual.
List the beginning date and end date (if applicable) when these data will be available. If the beginning date of data availability will be when the article is published, please indicate “with publication.”
■With publication
■At a date different from publication
●Beginning date
●End date (if applicable)
Supporting Documents
If your manuscript is accepted for publication, the journal will publish your trial protocol, including the statistical analysis plan, and any amendments as online supplements. Please list any other supporting documents that you wish to make available (eg, statistical/analytic code, informed consent form).
■Statistical/analytic code
■Informed consent form
■None
■Other (please specify)
List where to access these documents. Provide complete URL if the documents will be available in a repository or website, or provide complete email address if request for documents must be sent to an individual.
List the beginning date and end date (if applicable) when these data will be available. If the beginning date of data availability will be when the article is published, please indicate “with publication.”
■With publication
■At a date different from publication
●Beginning date
●End date (if applicable)
Additional Information
Indicate the types of analyses for which the data will be made available (eg, for any purpose or for a specified purpose).
Indicate the mechanism by which the data will be made available (eg, with investigator support, without investigator support, after approval of a proposal, or with a signed data access agreement).
List any additional restrictions on the use of the data or any additional information.
If you would like to offer context for your decision not to make the data available, please enter it below (optional).
Examples of Data Sharing Statements
● Example when data are not available
Data
Data available: No
Explanation for why data are not available: Data were collected before 2018 and the institutional review board did not approve the sharing of patient data.
● Example when data are available without any restrictions
Data
Data available: Yes
Data types: Deidentified participant data and data dictionary
How to access the data: Deidentified participant data and data dictionary have been deposited in Xyz Repository (xyzrepository.org/doi:10.1234/xyz.5abc123).
When available: With publication.
Supporting Documents
Document types: Statistical code and informed consent form
How to access documents: Statistical code has been deposited in Xyz Repository (xyzrepository.org/doi:10.1234/xyz.5abc123). Informed consent form included in Supplement 4.
When available: With publication.
Additional Information
Who can access the data: Anyone
Types of analyses: Any purpose
Mechanism of data availability: Without investigator support
Any additional restrictions: None
● Example when data are available with restrictions
Data
Data available: Yes
Data types: Deidentified participant data and data dictionary
How to access the data: Statistical code and informed consent form available from the corresponding author (authorname@email.edu).
When available: At a date different from publication: beginning month, day, year.
Supporting Documents
Document types: Statistical code and informed consent form
How to access documents: Statistical code and informed consent form available from the corresponding author (authorname@email.edu).
When available: At a date different from publication: beginning month, day, year.
Additional Information
Who can access the data: Researchers whose proposed use of the data has been approved
Types of analyses: For a specified purpose
Mechanism of data availability: With investigator support following a signed data access agreement
Any additional restrictions: Credit to the authors of the original study reporting these data required.
2.10.17 Additional Contributions.
Acknowledgment of other contributions and forms of assistance (eg, statistical review, preparation of the report, performance of special tests or research, editorial or writing assistance, or clerical assistance) also should be included. When individuals are named, their given names and highest academic degrees (see 2.2.3, Degrees) are listed, and it is recommended that their specific contributions and affiliations and whether they received compensation beyond their salaries for their assistance also be listed. Locations of the named institutions need not be included. For any individual named as providing additional contributions, the author should obtain written permission from that person indicating the person’s authorization to be so named (see 5.2.1, Acknowledging Support, Assistance, and Contributions of Those Who Are Not Authors, and 5.2.9, Permission to Name Individuals).
Additional Contributions: Talman Arad and Smardar Zaidman, PhD, Irving and Cherna Moskowitz Center for Nano and Bio-Nano Imaging, Weizmann Institute of Science, conducted the electron microscopy studies. Ana Tovar, MD, Institute of Pathology, Beilinson Hospital, assisted with electron microscopy data analysis. There was no financial compensation for these contributions.
Additional Contributions: Ellen Maki, PhD, assisted with statistical analysis, Michelle V. Lee, RN, obtained photographic data, and Hanna Fadzeyeva assisted in data collection. Dr Maki and Ms Fadzeyeva received financial compensation for their contributions.
Additional Contributions: The Branch Retinal Vein Occlusion Study Group is grateful for the contributions of the many referring ophthalmologists, without whom this study could not have been performed, and to the study patients, whose faithfulness to the study led to conclusions that promise hope for others with branch vein occlusion.
Additional Contributions: We thank Phani Darineni, MSc, Bruce Wollison, MSc, Sam Hunter, PhD, and Ryan Abo, PhD, for bioinformatics assistance. They were not compensated for their contributions beyond their established salaries.
Additional Contributions: The manuscript was copyedited by Linda J. Kesselring, MS, ELS, technical editor/writer, Department of Emergency Medicine, University of Maryland School of Medicine. She received no compensation beyond her salary for this contribution.
Many journals require authors to disclose any substantial writing and editing assistance and to recognize persons responsible for such assistance. Whether compensation was received for such assistance should be a part of the disclosure. This information should be included in the Acknowledgment section, and permission to be identified should be obtained from all named individuals (see 5.2.1, Acknowledging Support, Assistance, and Contributions of Those Who Are Not Authors). In such cases, institutional affiliations may be included.
Additional Contributions: We thank Heather Spielvogle, PhD, and Alexis Coatney, BA, Seattle Children’s Research Institute, for their assistance in editing and preparing the final manuscript as paid staff for the study.
Additional Contributions: We thank Petra Macaskill, PhD (School of Public Health, Sydney, Australia), for her comments on an early draft of the manuscript and her suggestions for its improvement. Dr Macaskill did not receive any compensation.
Additional Contributions: Lucia Taddio, BA, Erwin Darra, and Omar Parvez (all from The Hospital for Sick Children) provided assistance with data collection. Ms Taddio and Mr Darra received compensation from the study sponsor.
Additional Contributions: We thank Keijo Leivo, RN (Turku University Hospital; who was compensated for his contribution), and Tuukka Tikka, RN (Helsinki University Hospital; who was compensated for his contribution), for taking care of the logistics in this study. We thank Michael E. Moseley, PhD (Stanford University, Stanford, California; who received no compensation), for his invaluable advice and comments during preparation of the manuscript.
If identifiable patients are included in the article, their permission for publication should be obtained and such permission should be noted as follows (see 5.8.3, Patients’ Rights to Privacy and Anonymity and Consent for Identifiable Publication).
Additional Contributions: We thank the patient for granting permission to publish this information.
2.10.18 Additional Information (Miscellaneous Acknowledgments).
Occasionally, other types of information may be provided in the Acknowledgment section. However, permission or credit for reproduction of a figure or a table, even if modified, should be given in the figure legend or the table footnote, not in the Acknowledgment section (see 4.0, Tables, Figures, and Multimedia).
Additional Information: This is report 54 in a series on chronic disease in former college students.
Additional Information: This article has been reviewed by the Publications Committee of the Collaborative Study of Depression and has its endorsement.
Additional Information: This article is dedicated to the memory of my mentor, friend, and father, Clifford C. Lardinois Sr, MD.
Additional Information: A complete list of documents surveyed is available on request from the corresponding author.
Additional Information: The original data set is available from the New York State Department of Health, Albany.
Additional Information: The P sojae and P ramorum whole-genome shotgun projects have been deposited at DDBJ/EMBL/Genbank under the project accession numbers AAQY00000000 and AAQX00000000, respectively.
Additional Information: These documents are also available online (http://www.library.ucsf.edu/tobacco).
Additional Information: Additional studies are available from the UK Cochrane Centre, National Health Service Research and Development Programme, Summertown Pavillion, Middleway, Oxford OX2 7LG, England (ichalmers@cochrane.co.uk).
Additional Information: This article is the first of a 3-part series. The second part will appear next month.
2.10.19 Preferred Citation Format.
Some journals may choose to list a preferred citation format for each article to ensure correct citation. Some may do this only for articles for which citation problems or questions are likely to arise (eg, articles with group authors) (see 2.2.1, Authors’ Names, and 2.2.4, Multiple Authors, Group Authors). This information may be placed in the Article Information at the end of the print or PDF version of an article or on the article title page on the journal’s website. In many cases, this information is readily available online for specific articles or through links to online reference managers.